2016 American Transplant Congress
Appraisal of Alternative Immunosuppression Regimens in Intestinal Transplant Recipients: A Single Center Experience.
Purpose: The purpose of this study was to compare outcomes (acute cellular rejection, graft loss, mortality) in intestinal transplant recipients who were converted from the…2016 American Transplant Congress
High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.
Department of Nephrology, Charité Universitaetsmedizin, Berlin, Germany.
Introduction: Tacrolimus (Tac), the mainstay of immunosuppression in renal transplant (tx) patients (pts) is known for drug induced nephrotoxicity, which may limit graft survival.Methods: In…2016 American Transplant Congress
Steroid Use May Not Increase Risk of Fracture in Kidney Transplant Patients.
Introduction: Chronic steroid use is associated with bone mineral loss, and osteoporosis. However, it is not clear if chronic steroid use in post-kidney transplant patients…2016 American Transplant Congress
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.
Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI.
Background:The safety and effectiveness of tumor-necrosis-factor-α antagonist (anti-TNF-α) therapy for inflammatory bowel disease (IBD) has not been well-established in patients after liver transplantation (LT). We…2016 American Transplant Congress
Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Taclorimus with CsA for Two Years Result by a Japanese Multicenter Study.
Japanese Multicenter Study Group of High Dose Mizoribine in Kidney Transplantation, Kyoto, Japan.
(Aims) Mizoribine (MZR) has been developed as an immunosuppressive agent, but has a less potent immunosuppressive effect up to 3 mg/kg/day. The widespread use of…2016 American Transplant Congress
Long-Term Outcomes in Pediatric Live-Donor Liver Transplantation.
Aim: To determine the incidence of allograft and medical factors characterizing optimal patient outcomes 3 year or more after pediatric live-donor liver transplantation (LDLT). Methods:…2016 American Transplant Congress
Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas.
Division of Abdominal Transplantation, Stanford School of Medicine, Stanford, CA.
Epstein-Barr virus (EBV) B cell lymphomas in post-transplant lymphoproliferative disorder (PTLD) is a major problem in organ transplantation. Reduction of immunosuppression sometimes result in tumor…2016 American Transplant Congress
Rapamycin Encapsulated Nanoparticles as Pre-Treatment in Lung Transplantation.
Introduction: While short-term lung transplant outcomes have improved over the years, long-term survival rates remain stagnant. Many injuries occur to the donor organ before transplantation,…2016 American Transplant Congress
Everolimus (EVR) versus Mycophenolate Sodium (MPS) for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin (r-ATG) and Tacrolimus (TAC).
Introduction: There is no standard of care immunosuppressive regimen for recipients of kidneys recovered from expanded criteria donors. Several centers use r-ATG induction due to…2016 American Transplant Congress
The Optimal Time Point for Steroid Withdrawal After Kidney Transplantation Is One Year After Engraftment.
The optimal time of steroid withdrawal after kidney transplantation remains elusive, since RCTs can evaluate one predefined time point. Thus we analyzed all first kidney…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 138
- Next Page »